# Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Study · id `cardio:ct-nct07282743` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07282743](<https://clinicaltrials.gov/study/NCT07282743>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07282743

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 285 participants.

## Technical summary

Registry record NCT07282743. Randomized; triple masking; primary purpose treatment. Start 2026-01-20 (actual); primary completion 2027-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 285 participants (planned count; ClinicalTrials.gov record NCT07282743, source copy `cardio:ctgov-nct07282743-2026-03-18`, retrieved 2026-10-26)
- Started: 2026-01-20 (actual) (ClinicalTrials.gov record NCT07282743, source copy `cardio:ctgov-nct07282743-2026-03-18`, retrieved 2026-10-26)
- Primary completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT07282743, source copy `cardio:ctgov-nct07282743-2026-03-18`, retrieved 2026-10-26)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT07282743, source copy `cardio:ctgov-nct07282743-2026-03-18`, retrieved 2026-10-26)
- Countries: United States; India (ClinicalTrials.gov record NCT07282743, source copy `cardio:ctgov-nct07282743-2026-03-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07282743-2026-03-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Condition: Type II Diabetes Mellitus
- Intervention (Drug): GL0034 Dose Level 1
- Intervention (Drug): GL0034 Dose Level 2
- Intervention (Drug): GL0034 Dose Level 3
- Intervention (Drug): GL0034 Dose Level 4
- Intervention (Drug): GL0034 Dose Level 5
- Intervention (Drug): GL0034 Dose Level 6
- Intervention (Other): Placebo
- Lead sponsor: Sun Pharmaceutical Industries Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 776ff6194bdf547b595f5d9d8fec9d36e5c619b826467e483ca7bc29c83023c2
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
